Psychedelic Harm Reduction (Current Topics in Behavioral Neurosciences)

個数:

Psychedelic Harm Reduction (Current Topics in Behavioral Neurosciences)

  • 在庫がございません。海外の書籍取次会社を通じて出版社等からお取り寄せいたします。
    通常6~9週間ほどで発送の見込みですが、商品によってはさらに時間がかかることもございます。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合がございます。
    2. 複数冊ご注文の場合は、ご注文数量が揃ってからまとめて発送いたします。
    3. 美品のご指定は承りかねます。

    ●3Dセキュア導入とクレジットカードによるお支払いについて
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Hardcover:ハードカバー版/ページ数 567 p.
  • 商品コード 9783032211064

Description

Classic psychedelics such as psilocybin, LSD, ayahuasca, 5-MeO-DMT, and mescaline are multifaceted substances that have been used for healing and ritual purposes for millennia. In recent years, scientific interest in their therapeutic potential has resurged, yielding promising results for the treatment of mental health conditions, including depression, anxiety, and substance use disorders. At the same time, growing public interest and enthusiastic media coverage have contributed to increasing use in non-clinical contexts. Although psychedelics are considered not addictive and exhibit very low toxicity, their use can, in some cases, be associated with considerable risks and complications. To date, these risks remain underresearched, and many mental health professionals are insufficiently informed about their pathophysiology, differential diagnosis and clinical management. This book seeks to address this gap. From an interdisciplinary perspective, it aims to contribute to a more nuanced and balanced understanding of the benefit risk ratio and to offer practical guidance for managing complications that may arise when psychedelics are used in therapy and beyond. The chapter "Classifying Psychedelic-Related Complications" is available open access under the Creative Commons Attribution Non Commercial - No Derivatives 4.0 International License via link.springer.com.

Part I Classic Psychedelics and Harm Reduction.- Part II Psychedelic related Complications.- Part III Techniques of Psychedelic Harm Reduction.- Part IV Ethical Aspects.

Dr. med. Tomislav Majic: Licensed psychiatrist and psychotherapist in Berlin, Germany, with a focus on psychosis, substance use, double diagnosis and harm reduction. Studied medicine at Charité University Clinic Berlin until 2005. Co-founder and lead of  Psychedelic Substances Research Group" at Charité. Lecturer and supervisor for psychodynamic therapy at Berlin Institute for Psychotherapy and Psychoanalysis (BIPP). Founder of day clinic for patients with double diagnoses (2017) and outpatient treatment for patients suffering from psychedelic-related disorders (2017) ("Ambulanz Psychedelische Substanzen") at Psychiatric University Clinic of Charité at Hospital St. Hedwig Berlin. Study therapist and researcher  investigating therapeutic effects of classic psychedelics as well as psychedelic-related complications


最近チェックした商品